Alteration of the Total Nuclear DNA Ploidy in Different Histopathological Liver Tissues Negative and Positive for HCV RNA

Tabll, Ashraf A.; Kishta, Sara Sobhy; Farrag, Abdel Razik H.; Din, Noha G Bader El; Mohamed, Mervat S.; El, Yasmine S; Esawy, Basem H El; Kishta, Sobhy Ahmed; Dawood, Reham M.; A, Ismail; Awady, Mostafa K El

doi:10.7754/clin.lab.2015.141249

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, HCV RNA was measured in serum and liver tissue samples. The results demonstrated that 50% of patients were positive for HCV RNA in their sera samples while 69% had detectable HCV RNA in liver tissue [75]. The explanation of variation of detectable HCV viremia in sera samples and tissues is not clear, but it may be due to the activity of the immune system in peripheral blood and/or virus replication rate being higher in hepatocytes than in the peripheral blood [81,82].…”

Section: Patients With Hcv Hbv Hepatitis and Without Liver Diseases Progressionmentioning

confidence: 96%

“…In order to clarify our point, we focused on three main groups as shown in Table 1. 80% more tetra and aneuploidy as compared to HCV-negative-cirrhotic and fibrotic liver [75] --…”

Section: Hcvmentioning

confidence: 99%

“…Consequently, any cause of liver disease that may result in advanced fibrosis or cirrhosis should be considered as a potential risk factor for HCC development. Alterations in DNA content that could lead to liver disease progression, malignant transformation and development of HCC have been found in HCV positive liver tissue [75]. Ke et al [76] reported that HCV possesses the ability to activate numerous cellular responses, which consequently could participate in the pathophysiology of HCV-related liver disease through changes in lipid metabolism, interference with cell growth and/or cell proliferation and stimulation of the oncogenic signal pathway.…”

Section: Hcvmentioning

confidence: 99%

“…The image cytometry analysis was conducted in HCV positive and negative tissues. We assessed cellular kinetics in fibrotic and cirrhotic liver, and malignant hepatoma in HCV infected patients and compared their content to the positivity of HCV RNA [75]. Moreover, HCV RNA was measured in serum and liver tissue samples.…”

Section: Patients With Hcv Hbv Hepatitis and Without Liver Diseases Progressionmentioning

confidence: 99%

See 3 more Smart Citations

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

et al. 2020

Self Cite

View full text Add to dashboard Cite

Although hepatitis C virus (HCV) RNA may be eliminated from blood circulation by direct-acting antivirals (DAA) therapy as assessed by real-time polymerase chain reaction (PCR), HCV RNA can still be present in liver tissue, and this is known as occult HCV. There has been a lot of controversy surrounding the recurrence of hepatocellular carcinoma (HCC) after DAA treatment of hepatic cells infected with chronic HCV. One of the main risk factors that leads to de novo HCC is the chronicity of HCV in hepatic cells. There are many studies regarding the progression of HCV-infected hepatic cells to HCC. However, there is a lack of research on the different molecular mechanisms that lead to the progression of chronic HCV infection to HCC, as well as on the effect of HCV on the alteration of DNA ploidy, which eventually leads to a recurrence of HCC after DAA treatment. In this review article, we will address some risk factors that could lead to the development/recurrence of HCC after treatment of HCV with DAA therapy, such as the role of liver cirrhosis, the alteration of DNA ploidy, the reactivation of hepatitis B virus (HBV), the role of cytokines and the alteration of the immune system, concomitant non- alcoholic fatty liver disease (NAFLD), obesity, alcohol consumption and also occult HCV infection/co-infection. Clinicians should be cautious considering that full eradication of hepatocarcinogenesis cannot be successfully accomplished by anti-HCV treatment alone.

show abstract

Section: Patients With Hcv Hbv Hepatitis and Without Liver Diseases Progressionmentioning

confidence: 96%

“…In order to clarify our point, we focused on three main groups as shown in Table 1. 80% more tetra and aneuploidy as compared to HCV-negative-cirrhotic and fibrotic liver [75] --…”

Section: Hcvmentioning

confidence: 99%

Section: Hcvmentioning

confidence: 99%

Section: Patients With Hcv Hbv Hepatitis and Without Liver Diseases Progressionmentioning

confidence: 99%

See 2 more Smart Citations

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…About 71 million individuals are infected with HCV worldwide, in addition to 399,000 deaths occur due to HCV-associated liver diseases [2]. The directacting antiviral (DAA) therapy represents a breakthrough in HCV treatment, however there are still some limitations and complications of DAA therapy [1,3,45,46]. Furthermore, HCV vaccine development has not been successful, underscoring the importance of efficient therapies [7,8].…”

Section: Introductionmentioning

confidence: 99%

The non-structural proteins NS3 and NS5A of Hepatitis C Virus (HCV) are degraded by two host proteolysis systems

Mohamed,

Soppa

2023

Preprint

View full text Add to dashboard Cite

Hepatitis Virus C (HCV) is still a major medical challenge worldwide, with more than 70 million infected individuals. HCV is a 9.6 kb RNA virus that encodes a single polyprotein, which is split into 10 structural and non-structural (NS) proteins. The NS proteins are involved in various steps of the virus life cycle. They are required in much lower concentrations than the structural proteins, which are packaged in the viral particle. Nevertheless, they do not accumulate to very high concentrations, therefore, they must be degraded during an ongoing infection. In this study two non-structural proteins were chosen, NS3 and NS5A, and it was analyzed whether two major protein degradation pathways of the host are involved in their turnover. The half-lives of NS3 and NS5A were quantified in the absence and in the presence of modulators of the autolysosome and the proteasome. Inhibitors of both systems increased the half-life, while inducers decreased the half-life. In addition, polyubiquitination of NS3 and NS5A was observed, in agreement with their degradation via the proteasome. Furthermore, intracellular co-localization of both proteins with marker proteins for the autolysosome (LAMP2) and the proteasome (PSMB5) was observed using fluorescence microscopy, and inhibitors of both systems increased the degree of co-localization. Finally, the HCV replication complex was isolated using the membrane flotation assay, and the two autolysosome marker proteins LAMP2 and P62 were found in the same fractions. Taken together, various biochemical and cell biological assays provided evidence that both host proteolysis systems, the autolysosome and the proteasome, are involved in degrading HCV non-structural proteins, at least NS3 and NS5A. A better understanding of NS protein degradation might help to improve medical interventions during HCV infections in the future.

show abstract

Alteration of the Total Nuclear DNA Ploidy in Different Histopathological Liver Tissues Negative and Positive for HCV RNA

Cited by 2 publications

References 0 publications

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

The non-structural proteins NS3 and NS5A of Hepatitis C Virus (HCV) are degraded by two host proteolysis systems

Contact Info

Product

Resources

About